Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales BioSpaceAnalysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk's Wegovy pill.Metabolic & GLP-1Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) BioSpace Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. Metabolic & GLP-1 Read full story Post navigation Previous: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026Next: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026